Loading clinical trials...
Loading clinical trials...
Is Ibrutinib-related Atrial Fibrillation Dose Dependent: Insights From the WHO Pharmacovigilance Database
Conditions
Interventions
ibrutinib exposure
Locations
1
France
Caen University Hospital, Department of Pharmacology
Caen, Normandy, France
Start Date
March 1, 2024
Primary Completion Date
May 1, 2024
Completion Date
July 1, 2024
Last Updated
March 5, 2024
NCT07421076
NCT05537896
NCT07429214
NCT05976685
NCT04528511
NCT05147792
Lead Sponsor
University Hospital, Caen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions